26 Jul - 2 min read

Aspen confirms release of COVID-19 vaccines to Johnson & Johnson for supply to South Africa

Aspen confirms release of COVID-19 vaccines to Johnson & Johnson for supply to South Africa

(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Group”)


Aspen is pleased to confirm that the first supplies to South Africa of the Johnson & Johnson COVID-19
vaccines, from the new API source located in Europe, will be released to Johnson & Johnson from its
flagship Gqeberha-based manufacturing site later today. These vaccines will be further distributed
throughout South Africa in line with the various distribution arrangements between Johnson & Johnson,
the National Department of Health and other stakeholders. In addition, vaccines from these batches will
be made available through the African Vaccine Acquisition Task Team/African Union platform.

This represents a significant landmark for South Africa and Africa as these are the first COVID-19 vaccines
to be produced on the African continent, by an African producer for South African and African patients.
Supplies will also be made to the European Union and other offshore markets.

Aspen’s ability to produce these vaccines on behalf of Johnson & Johnson builds on its strategic vision of
delivering high quality, affordable medicines that improve health outcomes for patients in its home
country, South Africa, Africa and around the world. Supply for Africa and South Africa represents a big
step forward in ensuring that Africa can address its healthcare priorities. The manufacture of the Johnson
& Johnson COVID-19 vaccine builds on the global contributions Aspen has already made in fighting the
COVID-19 pandemic with both its anaesthetics portfolio and dexamethasone supply.

The full press release can be viewed on the news page of the Aspen website:

26 July 2021

Investec Bank Limited

Date: 26-07-2021 08:58:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Aspen Pharmacare Holdings Limited (JSE:APN) when you join Listcorp.